Syon Capital LLC Has $486,000 Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Syon Capital LLC cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 41.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,680 shares of the company's stock after selling 25,626 shares during the period. Syon Capital LLC's holdings in Takeda Pharmaceutical were worth $486,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical in the third quarter valued at approximately $40,000. Farther Finance Advisors LLC grew its position in Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at $52,000. Finally, Cromwell Holdings LLC bought a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at $61,000. 9.17% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK traded down $0.01 during midday trading on Wednesday, hitting $15.27. The stock had a trading volume of 414,348 shares, compared to its average volume of 1,860,479. The company's 50-day moving average price is $14.78 and its 200-day moving average price is $13.95. The company has a market capitalization of $48.59 billion, a P/E ratio of 38.18, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.37.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.